Paolillo Stefania, Della Ratta Giuseppe Luca, Vitagliano Alice, Cirillo Annapaola, Lardino Elisabetta, Formisano Tiziana, Fabiani Irma, Pellegrino Angela Maria, Riello Pietro, Filardi Pasquale Perrone
Department of Advanced Biomedical Sciences, Federico II University; Via Pansini 5, I-80131 Naples, Italy.
Monaldi Arch Chest Dis. 2013 Mar;80(1):27-30. doi: 10.4081/monaldi.2013.88.
Cardiovascular diseases represent the leading cause of morbidity and mortality worldwide, mostly contributing to hospitalizations and health care costs. Dyslipidemias represent one of the major cardiovascular risk factor and its management, throughout life-style modifications and pharmacological interventions, has shown to reduce cardiac events. The risk of adverse cardiovascular events is related not only to elevated LDL blood levels, but also to decreased HDL concentrations, that exhibit protective effects in the development of atherosclerotic process. Aim of this review is to summarize current evidences about defensing effects of such lipoproteins and to show the most recent pharmacological strategies to reduce cardiovascular risk through the increase of their circulating levels.
心血管疾病是全球发病和死亡的主要原因，在很大程度上导致了住院率和医疗费用的增加。血脂异常是主要的心血管危险因素之一，通过生活方式改变和药物干预对其进行管理已显示可减少心脏事件。不良心血管事件的风险不仅与血液中低密度脂蛋白（LDL）水平升高有关，还与高密度脂蛋白（HDL）浓度降低有关，HDL在动脉粥样硬化过程的发展中具有保护作用。本综述的目的是总结关于此类脂蛋白保护作用的当前证据，并展示通过提高其循环水平来降低心血管风险的最新药理学策略。
